Loading...
Loading...
Horizon Pharma, Inc.
today announced that RAYOS(R) (prednisone) delayed
release tablets are now available to U.S. physicians to treat a broad
range of diseases, including rheumatoid arthritis (RA), polymyalgia
rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis
(AS), asthma and chronic obstructive pulmonary disease (COPD). The
focus of the commercial launch will be in rheumatologic diseases,
such as RA and PMR. The Company will initially target approximately
one thousand rheumatologists in the U.S. with thirteen rheumatology
sales specialists. The full launch to the majority of U.S.
rheumatologists and high-value primary care physicians with Horizon's
entire sales force of approximately one hundred fifty representatives
will begin in late January 2013.
In July of this year, the U.S. Food and Drug Administration (FDA)
approved Horizon's new drug application (NDA) for RAYOS. The FDA
approval was supported by data bridging the pharmacokinetics of RAYOS
to immediate-release prednisone and data from the Circadian
Administration of Prednisone in RA (CAPRA-1 and 2) trials. The
CAPRA-2 trial demonstrated that people with moderate to severe RA
treated with RAYOS experienced a statistically significant
improvement in ACR20 response criteria compared to placebo in
addition to their non-biologic disease-modifying antirheumatic drug
(DMARD) therapy. The CAPRA-1 trial supported the overall safety of
RAYOS.
Specific results from CAPRA-2 demonstrated:
-- A statistically significant improvement in ACR20 response criteria,
the primary study endpoint, for patients who were treated with RAYOS
compared to the placebo group (47% vs. 29%; p-value = 0.001).
-- A statistically significant improvement in ACR50 response compared to
placebo (22% vs. 10%; p-value = 0.007) and an improvement in the more
stringent ACR70 response criteria (7% vs. 3%; p-value = 0.0984). Both
ACR50 and ACR70 were pre-specified secondary endpoints.
-- The relative change from baseline in the duration of morning stiffness
at 12 weeks was assessed as a pre-specified secondary endpoint.
Patients treated with RAYOS had a median decrease in the duration of
morning stiffness of 55 minutes compared to 33 minutes in
placebo-treated patients (20 minute estimated median difference
between treatment groups with 95% confidence interval [7, 32; p-value = 0.001]).
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in